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Introduction
Tegaserod has been used for treatment of irritable bowel syndrome (IBS) but there is no data regarding its effect on Korean 
patients. The aim of this study was to evaluate the effect of tegaserod on symptoms and quality of life (QOL) in Korean fe-
male IBS patients with constipation and to evaluate the usefulness of the IBS-QOL in clinical study. 
Methods
A prospective, open labeled, multicenter study was performed. Female patients fulfilling Rome II criteria for IBS received 6 mg 
of tegaserod twice a day for 4 weeks. The efficacy on IBS symptoms and QOL was assessed using 7-point scaled symptom 
questionnaire and IBS-QOL questionnaire, respectively.
Results
A total of 81 female patients (range 18-73 years of age) were enrolled in this study. Tegaserod therapy significantly reduced 
the overall symptom scores after 4 weeks (p ＜0.01). The improved symptoms included abdominal discomfort or pain, hard or 
lumpy stool, straining during a bowel movement, feeling of incomplete bowel movement, and abdominal fullness or bloating. 
The IBS-QOL of responders to tegaserod treatment was also significantly improved after 4 weeks (p ＜0.01). Furthermore, im-
provement of symptom scores significantly correlated with improvement of the IBS-QOL scores (r = -0.60, p ＜0.001).
Conclusions
Tegaserod 6 mg given twice daily improved the QOL as well as the bowel symptoms in Korean female IBS patients with 
constipation. The IBS-QOL can be used as a reliable end-point in clinical study.
(J Neurogastroenterol Motil 2010;16:61-70)
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Introduction
Irritable bowel syndrome (IBS) is a functional bowel 
disorder that is characterized by abdominal pain and the change 
of bowel habits in the absence of structural or biochemical 
abnormalities.
1 IBS is one of the most common gastrointestinal 
diseases encountered by gastroenterologists in clinical practice 
and affects up to 25% of the population in Western countries.
2-5 
Now IBS is increasing in Korea and a recent study reports the 
prevalence of 6.6% in the Korean population.
6 It is important to 
find a reliable end-point in clinical studies aiming to evaluate the 
efficacy of certain treatment modality in patient with IBS. The 
assessment of IBS symptoms is usually used as primary end-point 
in many clinical trials. However, patients with IBS suffer from 
not only the bowel related symptoms, but also from the poor 
quality of life (QOL) related to IBS. IBS has a negative impact 
on health related QOL and the therapeutic response of 
IBS-related symptoms has a corresponding improvement in 
health related QOL.
7-9
Among the limited therapeutic options, drugs acting on 
serotonin (5-hydroxytrypatmine, 5-HT) receptor have been 
widely used because serotonin plays a critical role in the 
gastrointestinal tract and has been shown to influence secretory, 
motor and sensory function in functional gastrointestinal 
disorders.
10 Tegaserod (Zelmac
Ⓡ; Novartis Pharma AG, Basel, 
Switzerland) is an indole carboxaldehyde derivative that acts as a 
selective partial agonist at the 5-HT4 receptor
11 and has been 
approved for the treatment of women with IBS with constipation 
(C-IBS) based on the results of previous clinical trials involving 
predominantly women. This drug has been proven more effective 
than placebo at improving global and individual symptoms in 
patients with C-IBS,
12,13 but has limited use in patients with IBS 
with diarrhea (D-IBS) because the augmented peristaltic reflex 
and accelerated colonic transit cause diarrhea, the most common 
adverse effect.
11
However, most clinical trials about the efficacy of tegaserod 
on IBS were conducted in Western countries,
12-15 and there are 
limited data from Asian countries.
16,17 Furthermore, there has 
been little data available about the relationship between symptom 
improvement and change in QOL after treatment with 
tegaserod,
18 and none in the Korean population.
The aim of this study was to evaluate the efficacy of treatment 
with tegaserod on symptoms of the IBS and to assess the impact 
on the QOL in female IBS patients with constipation in the 
Korean population. We also wanted to evaluate the usefulness of 
IBS-QOL assessment as well as IBS symptoms in clinical studies 
about IBS treatment.
Materials and Methods
1. Study design
This study was a prospective, open labeled study and was 
conducted by 13 researchers in 9 university hospitals of Korea 
who were members of the IBS Club of the Korean Society of 
Neurogastroenterology and Motility. Each participating 
researcher enrolled consecutive adult female IBS patients with 
constipation as the predominant symptom, between November 
2005 and February 2006. After checking the inclusion and 
exclusion criteria, the participating patients were asked to 
complete symptom questionnaire and IBS-QOL questionnaire 
as baseline data before treatment. Subsequently, 6 mg of 
tegaserod twice daily was administered for 4 weeks, and then 
symptom questionnaire and IBS-QOL questionnaire were 
completed again.
2. Patients
Patient selection was based on a 3-month history of IBS 
symptoms, diagnosed using the Rome II criteria.
19 Female 
patients, 18 years or older, were required to have abdominal pain 
or discomfort either relieved by a bowel movement, or associated 
with a change in the frequency of bowel movements or in the stool 
consistency. Patients were also required to have at least two of the 
following three constipation symptoms at least 25% of the time 
during the 3 months prior to study entry: less than three bowel 
movements per week, hard/lumpy stools or straining. In addition, 
patients with a mixed type of IBS could be enrolled if they 
showed a marked trend of constipation on the symptom severity 
questionnaire. Normal colonic anatomy had to be confirmed by 
colonoscopy or barium enema performed within 1 year. Patients 
were excluded from the study if they had a history of previous 
abdominal surgery (except appendectomy), state of pregnancy or 
lactation, severe systemic disease that could affect QOL, and any 
other significant digestive diseases (liver, pancreas, gall bladder, 
small, and large intestine). Patients who took medication specific 
for IBS (e.g., antidiarrheal, laxative, or antispasmodic drugs) 
within 6 months prior to the beginning of the study were also 
excluded. Medications affecting gastrointestinal motility and/or 
visceral perception, as well as antidepressants were not permitted Tegaserod Treatment in Korean Women
63 Vol. 16, No. 1 January, 2010 (61-70)
during the treatment period. However, synthetic fiber or 
laxatives were permitted as a rescue medication. 
3. Questionnaires
Bowel symptom and IBS-QOL questionnaire, which had 
been translated into Korean and validated in a previous linguistic 
and clinical study,
20 were used in the present study. These ques-
tionnaires also included demographic factors such as age, marital 
status, level of education, annual income, and other combined 
diseases.
1) Symptom questionnaire
This questionnaire included the Rome II criteria and 
assessment of severity for eight symptom variables. The symptom 
variables were as following: abdominal pain or discomfort; hard 
or lumpy stools; loose or watery stools; straining during a bowel 
movement; having to rush to the toilet for a bowel movement; a 
feeling of incomplete bowel movement; passing mucus (white 
material) during a bowel movement; abdominal fullness, 
bloating, or swelling. All variables were divided into frequency 
and bothersomeness index assessed by a 7 point Likert scale (0 =
never, 1 = almost never, 2 = seldom, 3 = sometimes, 4 =
often, 5 = almost always, 6 = always). Total symptom score was 
defined as the sum of the symptom frequency and 
bothersomeness scores. The potential range of frequency or 
bothersomeness sum-score for all symptoms was 0 to 48, and the 
range of total score was 0 to 96. All questions were related to the 
previous 4 weeks of changes.
We also measured self-reported symptom severity using the 
question ‘‘How bad is the discomfort usually?’’ and discomfort in 
this question implied ‘‘pain and associated IBS symptoms”. 
Responses were rated as mild (‘‘can be ignored if I don’t think 
about it’’), moderate (‘‘cannot be ignored, but does not affect my 
lifestyle’’), or severe (‘‘affects my lifestyle’’).
2) IBS-QOL questionnaire
Each patient also completed the IBS-QOL questionnaire 
initially developed by Patrick et al.
21 The Korean version of this 
questionnaire (K-IBS-QOL) has been cross-culturally validated 
and used in a subsequent study by Park et al.
20,22 It consists of 34 
IBS-specific items with high internal consistency and reprodu-
cibility. Patients were asked to choose descriptive statements 
using a recall period of the previous 30 days.
21 A five-point Likert 
scale was used to assess the degree of QOL by the statement 
describing the feelings of the respondent (1 = not at all, 2 =
slightly, 3 = moderately, 4 = quite a bit, 5 = extremely or a 
great deal). There were eight subscales: dysphoria interference 
with activities, body image, health worry, food avoidance, social 
reaction, sexual function, and relationships.
Subscales are scored through simple summative scaling. All 
items are negatively framed with the greatest response scale 
equaling the worst quality of life. When scored, all items are 
reversed so that as the IBS-QOL score increases, quality of life 
increases. All final raw scores are transformed into a 0 (poor 
quality of life) to 100 (maximum quality of life) scale using the 
following formula:
Scale score = {(the sum of the items - lowest possible score) /
possible raw score range} × 100
This transformation converted the lowest and highest 
possible scores into zero and 100, respectively. Scores between 
these values represented the percentage of the total possible score 
achieved. The IBS-QOL instrument and scoring programs have 
used this transformation to provide comparative data for 
interpretation. All items were sum-scored to calculate the overall 
score, which was also transformed into a 0-100 scale. If a patient 
responded with ‘‘not at all’’ for all 34 items, the overall score of 
IBS-QOL would be 100. If a patient responded with ‘‘slightly’’, 
a score of 4, for all items, the overall IBS-QOL score would be 
80. Therefore, if a score was more than 80, the subscale was not 
considered to be associated with bowel problems. Moderate to 
severe IBS had an approximate score of 60-65 by the 
IBS-QOL.
23
4. Statistical methods
Symptom score and IBS-QOL score at baseline and at end of 
treatment were compared using paired t test. The differences 
were considered statistically significant when a p-value ＜ 0.05 
was obtained. The ANOVA and Pearson’s correlation analysis 
were used to evaluate associations among patient’s characteristics; 
symptom score change and QOL score change. The responder 
was defined when there was a ≥ 2 point reduction of sum score 
of each symptom variables from baseline according to the 
previous study.
11,19 We used two endpoints for calculating the 
response rate. One was the change of abdominal pain or 
discomfort variable and the other was sum of changes of any 
significantly improved variables by tegaserod treatment (i.e., ≥ 2 
point reduction × number of improved variables).Y o n g  S u n g  K i m,  e t  a l
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Table 1. Demographic Characteristics, Symptoms and Quality of Life of All Patients
Factor n (%)
Total 
symptom score
(mean ± SD)
p-value
Overall 
QOL score
(mean ± SD)
p-value
Change of
total 
symptom score
(mean ± SD)
p-value
Change of
overall 
QOL score
(mean ± SD)
p-value
Total patients 81 (100%) 40.0 ± 16.8 70.5 ± 19.2   -9.1 ± 17.9   4.6 ± 17.1
Age group ＜30   9 (11.1%) 49.2 ± 11.5 NS 63.8 ± 21.5 NS -21.1 ± 16.8 NS 15.1 ± 15.2 NS
≥30, ＜40 20 (24.7%) 42.2 ± 19.3 73.1 ± 18.1 -11.5 ± 17.4   7.2 ± 13.0
≥40, ＜50 14 (17.3%) 45.0 ± 18.9 66.6 ± 20.3   -4.8 ± 15.3   1.8 ± 20.0
≥50, ＜60 20 (24.7%) 33.0 ± 15.7 71.9 ± 22.6   -9.1 ± 20.1   6.1 ± 16.6
≥60 18 (22.2%) 36.7 ± 12.8 72.2 ± 14.5   -3.9 ± 16.8  -3.2 ± 18.3
Duration ＜2 years 25 (30.9%) 38.1 ± 18.4 NS 74.9 ± 18.4 NS   -7.1 ± 20.2 NS   3.4 ± 19.4 NS
2-4 years 10 (12.3%) 36.6 ± 17.9 61.2 ± 23.7   -9.3 ± 24.2 10.9 ± 19.8
＞4 years 46 (56.8%) 41.7 ± 15.8 70.1 ± 18.1 -10.2 ± 15.3   3.9 ± 15.2
Number of <2/6 months 46 (56.8%) 36.9 ± 17.3 ＜0.05 76.1 ± 17.9 ＜0.01   -9.5 ± 18.5 NS   3.9 ± 18.3 NS
 hospital visit 2-4/6 months 20 (24.7%) 38.5 ± 13.6 66.0 ± 17.2   -6.8 ± 15.5   2.7 ± 13.7
＞4/6 months 15 (18.5%) 51.3 ± 15.4 59.4 ± 20.1 -11.1 ± 20.1   9.0 ± 18.0
Self-reported Mild   4 (4.9%) 34.5 ± 32.0 NS 64.7 ± 24.9 ＜0.01     0.3 ± 21.7 NS  -1.3 ± 17.2 NS
 symptom Moderate 33 (40.7%) 36.2 ± 16.6 78.3 ± 17.1 -10.5 ± 15.7   4.1 ± 14.4
 severity Severe 44 (54.3%) 43.4 ± 15.0 65.1 ± 18.6   -8.9 ± 19.3   5.5 ± 19.2
Level of Less than high school 21 (25.9%) 37.4 ± 18.5 NS 69.1 ± 16.4 NS   -8.9 ± 18.8 NS   2.1 ± 17.6 NS
 education High school 29 (35.8%) 38.7 ± 18.8 72.0 ± 21.5   -4.2 ± 19.5   1.5 ± 17.6
More than high school 31 (38.3%) 43.0 ± 13.4 69.9 ± 19.1 -13.8 ± 14.9   9.1 ± 15.9
Marital Married 55 (67.9%) 38.8 ± 16.7 ＜0.05 72.0 ± 20.1 NS   -7.4 ± 17.8 NS   2.6 ± 18.3 NS
 status Single   7 (8.6%) 30.1 ± 18.7 63.2 ± 14.4   -4.7 ± 22.8   9.0 ± 10.6
Divorced/Bereavement 19 (23.5%) 47.1 ± 14.3 68.9 ± 18.1 -15.8 ± 15.6   8.6 ± 15.2
Annual ＜$20,000 17 (20.9%) 41.6 ± 18.1 NS 70.9 ± 17.0 NS   -8.6 ± 14.1 NS  -2.9 ± 16.6 NS
 income
a $20,000-$40,000 13 (16.0%) 40.4 ± 15.9 69.7 ± 19.1   -6.0 ± 14.6 3.7 ± 8.7
＞$40,000 15 (18.5%) 42.9 ± 20.1 72.8 ± 19.6 -17.6 ± 23.0 10.4 ± 26.1
aThirty six patients (44.4%) did not respond to this question.
SD, standard deviation; QOL, quality of life; NS, not significant.
Table 2. Summary of the Baseline Symptoms among 81 Patients
Symptoms
Number (%) 
of affected 
patients
Mean 
score of all 
patients
Fewer than three bowel movements a week 65 (80.2)
More than three bowel movements a week   4 (4.9)
Abdominal pain or discomfort 81 (100) 6.38
Hard or lumpy stool 63 (77.8) 5.54
Loose or watery stool 20 (24.7) 3.54
Straining during bowel movement 63 (77.8) 6.35
Urgency 14 (17.3) 3.33
Feeling of incomplete bowel movement 70 (86.4) 6.79
Passing mucus 18 (22.2) 1.47
Abdominal fullness, bloating, or swelling 65 (80.3) 6.58
Results
1. Baseline characteristics of patient
A total of 81 female patients from 9 centers were enrolled in 
this study. All patients were women aged 18-73 years. Table 1 
showed the demographic features for all 81 female participants 
and both their symptom score and QOL score. The mean age of 
total participants was 46.2 years, 56.8% had the disease for over 4 
years and 67.9% were married. Age, duration of disease, level of 
education, and economic status did not affect the baseline symp-
tom score or QOL score, but total symptom score differed ac-
cording to marital status. Number of hospital visits showed good 
correlation with both total symptom score (＜ 0.05) and QOL 
score (p ＜ 0.01) (Table 1). 2. Baseline symptom score and IBS-QOL score
Frequently reported symptoms of subjects on the baseline Tegaserod Treatment in Korean Women
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Figure 1. Baseline IBS-QOL score of all patients (n = 81). The dys-
phoira, health worry, and food avoidance subscales showed 
the greatest impairments among 8 subscales. The sexual 
function subscale was not considered to be associated with 
bowel problems. 
Figure 2. The change of irritable bowel syndrome  symptoms after treatment of tegaserod. (A) The overall symptoms scores, symptom frequency and
symptom bothersomeness were improved after 4 weeks of therapy. (B) Tegaserod improved abdominal pain or discomfort, hard or lumpy
stool, straining during bowel movement, feeling of incomplete bowel movement, and abdominal fullness or bloating among eight symptom
variables. *p < 0.01. F, fullness; B, bloating; S, swelling.
symptom questionnaire were incomplete bowel movement, 
abdominal bloating, fewer than three bowel movements a week, 
hard or lumpy stool, and straining during bowel movement in 
order of prevalence (Table 2). Self-reported severity of their 
bowel symptoms classified as mild, moderate and severe was 5%, 
40.7%, and 54.3%, respectively. Self-reported symptom severity 
significantly correlated with baseline QOL score (r = -0.23, p
＜ 0.05) but not with baseline symptom score. Fig. 1 showed the 
baseline IBS-QOL score of patients. Of the 8 subscales, the 
greatest impairments (i.e., scores below 65) were seen with 
dysphoira, health worry, and food avoidance subscales. The score 
of sexual function subscale was 86.85, therefore it was not 
considered to be associated with bowel problems. The dysphoria, 
interference with activities, body image, health worry, social 
reaction subscales (r = -0.47, -0.46, -0.48, -0.46, and -0.51 
respectively, p ＜ 0.001) and overall IBS-QOL score (r =
-0.52, p ＜ 0.001) showed a stronger correlation with symptom 
score than the food avoidance and relationships subscales (r =
-0.38 and -0.39, p ＜ 0.001).
3. Symptom score outcome
Tegaserod significantly improved overall symptoms score, 
symptom frequency and symptom bothersomeness after 4 weeks 
of therapy (Fig. 2A). The response rate using the abdominal pain 
or discomfort variable was 49.4% (40/81) and their mean 
decreased score was 4.43. In analysis of individual variables, 
tegaserod significantly improved abdominal pain or discomfort, 
hard or lumpy stool, straining during bowel movement, feeling of 
incomplete bowel movement, and abdominal fullness or bloating 
(p ＜ 0.01). But tegaserod did not influence loose or watery Y o n g  S u n g  K i m,  e t  a l
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Table 3. Response Rate according to Symptom Score Variables
Variables
≥ 2 point decrement from baseline ≥ 2 point increment from baseline
Number of 
patient (%)
Mean score change 
of responders
Number of 
patient (%)
Mean score change 
of responders
Abdominal pain or discomfort 40 (49.4) -4.43 10 (12.3) +4.40
Hard or lumpy stool 39 (48.1) -5.05 11 (13.6) +4.82
Loose or watery stools 28 (34.6) -4.04 18 (22.2) +5.00
Straining during bowel movement 43 (53.1) -5.40 12 (14.8) +4.00
Urgency 30 (37.0) -3.47 21 (25.9) +4.71
Feeling of incomplete bowel movement 40 (49.4) -4.60 20 (24.7) +3.35
Passing mucus 13 (16.1) -4.15 17 (21.0) +3.53
Abdominal fullness, bloating, or swelling 42 (51.9) -4.36 15 (18.5) +4.00
Figure 3. The baseline symptom score according to responders and 
nonresponders. When patients were divided into responders
and nonresponders, the baseline scores of five improved 
symptom variables were significantly higher in responders 
than nonresponders, but there was no difference of baseline 
QOL score between responders and nonresponders. *p<  
0.05, **p < 0.01. F, fullness; B, bloating; S, swelling.
stools, urgency, or passing mucus (Fig. 2B). The response rate 
that was calculated by a ≥ 10 point reduction in sum-score of 
five significantly improved variables from baseline was 43.2% 
(35/81) and their mean decreased sum score was 22.54. We used 
this value as the reference for definition of responder and analysis 
of QOL in this study. The baseline scores of these five symptom 
variables were significantly higher in responders than 
nonresponders (Fig. 3). A small portion of patients reported that 
their symptoms were aggravated after tegaserod therapy, even 
with the above five significantly improved variables, and 
interestingly 24.7% of patients reported that the feeling of 
incomplete bowel movement was aggravated after medication 
(Table 3). Unlike the basal symptom score, there was no 
significant correlation between demographic factors and the 
degree of improvement of symptom scores (Table 1), and there 
was no statistical difference in demographic factors between 
responders and nonresponders.
4. Quality of life outcome
Tegaserod significantly improved the overall IBS-QOL 
score after 4 weeks (p ＜ 0.05). After treatment, the overall 
IBS-QOL score increased in 67.9% of patients compared to the 
baseline. In analysis of individual subscales between pre- and 
post-treatment for all patients, tegaserod significantly improved 
dysphoria, body image, health worry, and food avoidance 
subscales. But tegaserod did not influence interference with 
activities, social reaction, sexual function, and relationships 
subscales (Fig. 4A). Unlike the basal QOL score, there was no 
significant correlation between demographic factors and the 
degree of improvement of QOL score (Table 1). There was also 
no significant difference in baseline QOL score between 
responders and nonresponders.
5. Relationship between improvement of symptoms and 
QOL change
We analyzed individual subscales of QOL at pre- and post- 
treatment period according to responders and nonresponders. All 
QOL subscales except the sexual function subscale were 
significantly improved by tegaserod treatment in the responders 
with the greatest changes in dysphoria and social reaction 
subscale (Fig. 4B). However, no subscale was improved in Tegaserod Treatment in Korean Women
67 Vol. 16, No. 1 January, 2010 (61-70)
Figure 4. The change of IBS-QOL score after treatment of tegaserod.
(A) Dysphoria, body image, health worry, and food 
avoidance subscale among eight subscales were improved 
after 4 weeks of therapy. When patients were divided into 
responders and nonresponders, there was a significant 
improvement of all subscale except sexual function subscale 
in responders (B), but no subscales were improved in 
nonresponders (C). *p ＜ 0.05, **p ＜ 0.01. DY, dyspho-
ria; IN, interfere with activity; BI, body image; HW, health 
worry; FA, food avoidance; SR, social reaction; SX, sexual; 
RL, relationship; OV, overall.
nonresponders and the QOL scores were rather decreased except 
the health worry subscale, but this decrease was not significant 
(Fig. 4C).
To evaluate the relationship between degree of symptomatic 
improvement and QOL improvement, we divided patients into 
three response categories using the sum-scores of above five 
symptom variables (improving: decrease ≥ 10 point; no change: 
decrease or increase ＜ 10 point; worsening: increase ≥ 10 point 
from pre- to post-treatment). Patients with more symptomatic 
improvement showed a greater increase in IBS-QOL score (Fig. 
5A). The overall IBS-QOL score change of 12.26 from pre- to 
post-treatment in an improving group is significantly greater than 
no change (p < 0.01) or worsening group (p < 0.01), but there 
was no significant difference between no change and worsening 
group (p > 0.05). There was a strong correlation between the 
improvement of symptom score and improvement of individual 
IBS-QOL subscale score or overall IBS-QOL score (Fig. 5B, r
= -0.60, p ＜ 0.001).
Discussion
This nationwide, multicenter, prospective study is the first to 
report the therapeutic impact of tegaserod on QOL in Korean 
female patients with IBS. IBS is widely distributed in Western 
and Eastern countries and tegaserod has been used for IBS 
treatment worldwide including in Korea. Tegaserod was 
approved for the treatment of female patients with IBS-C in July 
2002.
11,18 Although tegaserod was removed from the worldwide 
market in March 2007 because of the possible cardiovascular 
adverse effects, it is still worthwhile to evaluate their efficacy in 
patients with IBS for further development of serotonergic drugs 
for the management of IBS. The present study demonstrated that 
tegaserod improved abdominal pain or discomfort, hard or lumpy 
stool, and bloating in spite of its short treatment duration. This Y o n g  S u n g  K i m,  e t  a l
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Figure 5. Changes in IBS-QOL in subgroups by clinical responses and correlation between symptom change and quality of life  change. (A) There
was a strong negative correlation between total symptom score change and quality of life score change. The more symptom score decreased,
the more quality of life score improved. If symptom was aggravated after treatment, quality of life was aggravated with greater score 
reduction in interference with activities, social reaction, and relationship subscales than other subscales. (B) There was a strong negative 
correlation between the improvement of five symptom score (sum of abdominal pain or discomfort, hard or lumpy stool, straining during
bowel movement, feeling of incomplete bowel movement, and abdominal fullness or bloating) and overall IBS-QOL score (r = -0.60, p
< 0.001). Correlations with symptom score of other subscales were also significant (R = DY -0.57; IN -0.54; BI -0.52; HW -0.43; FA
-0.44; SR -0.55; SX nonspecific; RL -0.46, p ＜ 0.001). *p < 0.05, **p < 0.01. DY, dysphoria; IN, interfere with activity; BI, body 
image; HW, health worry; FA, food avoidance; SR, social reaction; SX, sexual; RL, relationship; OV, overall; TSS, total symptom score.
result is consistent with that of the previous studies.
12,13,15,18 
Tegaserod not only significantly accelerates gastric emptying and 
transit time of small bowel and colon but also reduces the 
sensitivity to rectal distension. Our study also showed that 
straining and feeling of incomplete bowel movement were 
improved and this result supports the theory that tegaserod 
affects visceral sensation as well as gastrointestinal motility.
24,25 
However, the Asian-Pacific population study did not 
demonstrate a significant differences in these two symptoms
17 
and this inconsistency of results may be due to differences in 
study design and population.
The response rate of clinical studies depends on race, region 
and treatment duration. IBS patients experience multiple 
symptoms and there is no definite biomarker, therefore it is very 
important to choose the proper primary end-point in the clinical 
trial that evaluates the efficacy of therapeutic drugs on IBS. The 
response rate in studies using the Subject’s Global Assessment 
(SGA, question like “Did you have satisfactory relief of your 
overall IBS symptoms during the treatment period?”) was 56% 
for 4 weeks in Asian population,
17 40.5% for 4 weeks in US 
population,
13 and 30.5% for 4 weeks
14 and 46.3% for 12 weeks
12 
in European population. In the most recent, largest (n = 2,660), 
multinational study of Western countries, the response rate was 
41.8% for 4 weeks.
16 Although some guidelines recommended to 
use subjective symptomatic relief as a primary end-point and it 
has been commonly used in most clinical trials, these parameters 
could not capture the entire effect on individual symptoms and 
may have underestimated the effectiveness of the drug.
26,27 The 
IBS patients with mild baseline symptoms were more likely to 
report satisfactory relief than those with moderate or severe 
symptoms. Conversely, the IBS patients with severe baseline 
symptoms showed the greatest reduction in symptom score but 
were least likely to report satisfactory relief.
28 For this reason, we 
assessed eight individual symptom scores before and after 
treatment as the primary end-point instead of SGA in this study. 
Novic et al.
13 reported that tegaserod was associated with a 
statistically significant higher improvement than placebo and 
mean score differences (end-point minus baseline of bothersome 
score) of tegaserod/placebo in abdominal pain and bowel habit 
were -1.01/-0.80 and -1.30/-0.95, respectively. Based on this 
result and other clinical study,
15 we defined the responder in this 
study as a ≥ 2 point reduction from baseline sum score 
(frequency plus bothersomeness) and the response rate of 
abdominal pain/discomfort was 49.4%. This result is comparable 
with the response rate (47.8%) for abdominal discomfort/pain in 
the recent largest, multinational Western study which used Tegaserod Treatment in Korean Women
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similar definition.
15
IBS-specific quality of life has rarely been used as a primary 
end-point in the assessment of the effect of tegaserod on IBS, but 
IBS patients suffer from impaired health-related QOL as well as 
their IBS-related bowel symptoms.
7-9 Therefore, it is useful to 
evaluate the effect on QOL of patients with IBS by certain 
medication in clinical trials. However most clinical studies 
usually assessed symptomatic improvement or used only a 
summary score even if QOL was assessed. The pattern of bowel 
symptoms related to IBS seems to be similar across the country,
29 
but quality of life perceived by IBS patients varied depending on 
different cultural environments and countries rather than racial 
differences.
30,31
In the current study, the subscales with low scores (60-65) 
that can be considered as moderate to severe IBS were dysphoria, 
health worry, and food avoidance subscale and the score of health 
worry subscale was lowest. This result suggests that IBS patients 
suffer more from anxiety about their disease than impairment of 
social activity or relationship by bowel symptom. This poor QOL 
is an important factor that causes patients to consider their disease 
severe and self-reported severity only significantly correlated with 
QOL score, but not symptom score. For this reason, the 
a s s e s s m e n t  o f  I B S - Q O L  s h o u l d  b e  i n c l u d e d  a s  p a r t  o f  t h e  
therapeutic outcome in clinical trials that assess the efficacy of 
certain drugs on IBS patients.
The score of sexual function subscale was over 80 points and 
was not affected by tegaserod therapy in the present study, but 
there was a possibility that subjects did not report their actual 
sexual life. Koreans, especially females who make up the current 
study population, are reluctant to express sexual problems and 
this tendency was already observed in the previous study.
20
There was no difference of baseline QOL between 
responders and nonresponders, but QOL was significantly 
improved in responder group. Interestingly, if symptom was 
aggravated after treatment, there was a tendency of decrease in 
QOL with greater score reduction in the subscales of interference 
with activities, social reaction, and relationship than other 
subscales. This result suggests that as bowel symptoms become 
severe, the QOL about social activity is more impaired than the 
QOL about disease-related worry.
Based on these results, it is suggested that we should try the 
bowel-directed treatment first, for the IBS-related anxiety and 
poor QOL and then if there is no improvement by this general 
management, additional treatment modality, such as antidepre-
ssant or psychiatric treatment, should be considered.
We found a strong inverse correlation between baseline 
symptom score and QOL score and good categorization of QOL 
score change according to symptomatic response group to 
tega sero d  trea tm en t.  In  a sp ect o f u sefu ln es s o f IB S - Q O L  in 
clinical studies for IBS treatment, therefore, it seems to be used as 
a primary end-point and has a role in support of subjective 
symptomatic end-point to evaluate and monitor efficacy of certain 
drug. Additionally IBS-QOL can characterize the patients 
according to their responsiveness and acts as an indicator for the 
clinical course of patients with IBS under treatment.
This study has limitations since it was not a placebo 
controlled study and there has been no consensus about the 
definition of responder in the scoring system. We used p-value
＜ 0.05 or ≥ 2 point reduction from baseline score as response 
indicator according to previous study, but p-value or certain 
reduction of score do not imply whether a particular finding has 
clinical implications. 
Until now, there have been few available data from 
well-designed studies about the impact of tegaserod on QOL. 
Therefore, it is necessary to study about the clinically meaningful 
threshold of scoring system and more clinical trials using 
IBS-QOL questionnaire for specific culture, nation, and race are 
needed.
In conclusion, current results suggest that tegaserod 6 mg 
twice daily is effective for improvement of the QOL as well as the 
bowel symptoms in Korean female patients with IBS whose 
primary symptom is constipation. In addition, the IBS-QOL can 
be used as a reliable end-point in IBS clinical study and provide 
with additional useful information in clinical practice.
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